Masimo Corporation

717 articles about Masimo Corporation

• Masimo Announces FDA 510(k) Clearance of Radius Tº™ for Prescription and Over-the-Counter (OTC) Use

  6/21/2021

  Masimo announced today that Radius Tº™, a wearable, wireless thermometer that measures body temperature continuously and noninvasively, has received FDA 510(k) clearance for both prescription and over-the-counter (OTC) use on patients and consumers five years and older.

• New Study Investigates the Impact of ORi-Guided Oxygen Titration on Hyperoxemia-Mediated Morbidity During One-Lung Ventilation

  6/14/2021

  Masimo announced the findings of a study published in the Turkish Journal of Medical Sciences in which Dr. Ayten Saracoglu and colleagues at the Marmara University Pendik Training and Research Hospital in Istanbul evaluated the ability of ORi to guide oxygenation by measuring its impact on hyperoxemia-mediated morbidity during one-lung ventilation conducted as part of thoracic surgery.

• Masimo to Present in UBS Global Healthcare Virtual Conference

  5/19/2021

  Masimo announced that its management is scheduled to participate in the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 2:00 p.m. Eastern Time.

• New Study Assesses the Effects of Masimo Patient SafetyNet™ on Nursing Workflows in the General Ward

  5/17/2021

  Researchers Found That Use of Patient SafetyNet with Masimo SET® Pulse Oximetry and Acoustic Repsiratory Rate (RRa®) Monitoring Reduced Nursing Workload Related to Postoperative Respiratory Assessment by More Than 60%

• Study Investigates the Ability of Masimo O3® to Aid in Monitoring Septic Shock ICU Patients and Predicting Mortality

  5/10/2021

  Researchers Found That O3 May Help Clinicians Rapidly Assess Circulatory Status in Patients Experiencing Septic Shock and Have Prognostic Value in Mortality Prediction

• Study Investigates the Ability of Masimo PVi® to Predict Preload Responsiveness in Patients On Nasal High-Flow Therapy

  5/3/2021

  Masimo announced the findings of a study published in the Journal of Applied Physiology in which Dr. Marina García-de-Acilu and colleagues at the Vall d’Hebron University Hospital in Barcelona evaluated the utility of Masimo PVi® as a noninvasive method of predicting preload responsiveness in patients treated with nasal high-flow therapy.

• Masimo Reports First Quarter 2021 Financial Results

  4/26/2021

  First Quarter 2021 Highlights Product revenue increased 10.9% to $299.0 million, or 9.5% on a constant currency basis; GAAP net income per diluted share was $0.92; and Non-GAAP net income per diluted share was $0.90.

• Masimo to Report First Quarter 2021 Financial Results after Market Close on Tuesday, April 27

  4/14/2021

  Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)

• Masimo Announces FDA Clearance of Radius PCG™ for the Root® Patient Monitoring and Connectivity Platform

  4/12/2021

  Masimo Announces FDA Clearance of Radius PCG™ for the Root ® Patient Monitoring and Connectivity Platform Radius PCG with Bluetooth ® Connectivity Seamlessly Integrates Tetherless Mainstream Capnography with Root

• Study Investigates the Effects of Ventilatory Rescue Therapies on the Cerebral Oxygenation of COVID-19 Patients Using Masimo O3®

  4/6/2021

  Study Stresses the Importance of Brain Monitoring During the Treatment of Patients with Severe COVID-19

• Study Investigates the Impact of Automating Respiration Rate Measurement Using Masimo Rad-G™ with RRp®

  3/29/2021

  Masimo announced the results of a prospective, observational study published in Acta Paediatrica in which researchers from the Hospital for Sick Children in Toronto evaluated the accuracy of plethysmographic respiration rate measurement using Masimo Rad-G™, a rugged, handheld device, on malnourished, hospitalized children in Nigeria.1

• Sri Lankan Study Expands Evidence Demonstrating the Benefits of Critical Congenital Heart Disease (CCHD) Screening Using Masimo SET® Pulse Oximetry

  3/22/2021

  Masimo announced the results of a prospective study published in the Sri Lanka Journal of Child Health in which researchers in Colombo, Sri Lanka evaluated the efficacy of a pulse oximetry-based critical congenital heart disease newborn screening strategy using Masimo SET® pulse oximetry.1 The authors concluded that pulse oximetry is a “simple, noninvasive, cost-effective, feasible, and reliable test,” and found that it had higher CCHD screening sensitivity than physical exam.

• New Study Evaluates the Ability of Masimo EMMA® Capnography to Assess the Respiratory Status of Children With Tracheostomy

  3/15/2021

  Masimo announced the findings of an observational, retrospective study published in Pediatrics International.

• Masimo Monitoring Solutions Promote Newborn and Maternal Safety

  3/8/2021

  New Neonatal Study Adds to Body of Clinical Evidence Demonstrating Masimo SET® Pulse Oximetry’s Unique Ability to Improve Care

• Masimo Announces CE Marking of the Rad-G™ with Temperature

  3/2/2021

  Masimo announced the CE marking of the Rad-G™ with Temperature, a rugged handheld device that provides clinically proven SET® pulse oximetry, respiration rate from the pleth, and other important parameters alongside clinical-grade, non-contact infrared thermometry.

• Masimo to Report Fourth Quarter and Full Year 2020 Financial Results after Market Close on Tuesday, February 23

  2/16/2021

  Masimo will release fourth quarter results at Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)

• Masimo Announces Full Market Release of Masimo SafetyNet-OPEN™

  2/15/2021

  Easy-to-Implement Solution Helps Businesses, Schools, and Other Organizations Reopen Responsibly and Stay Open Safely During Infectious Illnesses

• Masimo Announces the iSirona™ Connectivity Hub

  1/19/2021

  Masimo (NASDAQ: MASI) today announced the global launch of iSirona ™ , a compact, versatile connectivity hub designed to maximize interoperability across the continuum of care. The iSirona hub offers an efficient way to physically connect up to six medical devices at the bedside and automatically route the data to the Masimo Hospital Automation ™ platform, a vendor-agnost

• Masimo Helps Clinicians at Renown Health Manage the COVID-19 Surge

  12/21/2020

  Masimo announced that Masimo is helping clinicians at Renown Health in Reno, Nevada, to address the COVID-19 surge, including through use of Masimo SafetyNet™, a remote patient management platform.

• Researchers Use Masimo ORi™, Oxygen Reserve Index, to Help Suppress Postoperative Hyperoxia in Patients Undergoing Breast Surgery

  12/14/2020

  Masimo announced the findings of an abstract recently presented at Euroanaesthesia 2020 in which Dr. Kumagai and colleagues at Iwate Medical University Hospital in Yahaba-cho, Japan investigated whether Masimo ORi™, Oxygen Reserve Index, could be used to limit the extent of postoperative hyperoxia.1 The researchers concluded that ORi helped “suppress hyperoxia, preventing hypoxia.”.